|Day's Range||33.88 - 34.07|
|52 Week Range||25.55 - 35.60|
|PE Ratio (TTM)||25.51|
|Dividend & Yield||1.90 (5.65%)|
|1y Target Est||N/A|
IBD's 439-company Biotech industry group is now ranked fourth out of 197. How far can the rally go?
Pharma sector second quarter earnings season has started with industry bellwether Johnson & Johnson (JNJ) reporting earlier this week while AstraZeneca and Merck provided regulatory updates.
AstraZeneca Chief Executive Pascal Soriot, responding to rumors he might leave the drugmaker to join rival Teva Pharmaceutical Industries, has told staff he expects to work "together" with employees to see the company succeed. A company spokeswoman added he was intending to attend the European Society for Medical Oncology annual meeting in Madrid in September, assuming that AstraZeneca had clinical data on its new immunotherapy medicine ready to present at the event. Soriot did not comment on whether he had received a job offer from Teva in the internal memo to staff, which was sent out at the start of this week.